| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8441954 | European Journal of Cancer | 2015 | 10 Pages |
Abstract
More drugs are assessed in Spain than by NICE because there are more organisations in Spain doing this work and their processes are simpler. NICE rejects more drugs as it uses cost-effectiveness thresholds that lead to a 'not-recommended' decision, and Spanish bodies recommend cancer drugs for subgroups of patients where better results can be obtained. Timelines are better for Spanish Committees, probably because of the greater number of steps in the appraisal process by NICE.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Ana Lozano-Blázquez, Rumona Dickson, MarÃa-Dolores Fraga-Fuentes, Fernando MartÃnez-MartÃnez, Miguel-Ángel Calleja-Hernández,